Lupin receives tentative approval from USFDA for Canagliflozin Tablets
Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor
Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor
This product will be manufactured at Lupin’s Pithampur facility in India
The supplemental New Drug Application is based on results from the landmark EMPA-KIDNEY phase III trial
Routine tests undertaken by women dropped by 35% in 2020
Subscribe To Our Newsletter & Stay Updated